


**ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC
ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS**

Abstract

Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals

5

The present invention relates to compounds of the formula I,



I

- 10 wherein A, Y, Z, R³ to R⁶, R²⁰ to R²² and R⁵⁰ have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA₁ receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial
- 15 infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

[No Fig.]